The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | The work of the Elf Lab: understanding MPN driver mutations and cell types
In this video, Shannon Elf, PhD, University of Utah School of Medicine, Salt Lake City, UT, briefly provides insight into the research focus of her lab, highlighting that she and her team are currently aiming to better understand the driver mutations in myeloproliferative neoplasms (MPNs) and to improve the knowledge of the metabolic dependencies of the mutant stem cell compartment. Dr Elf emphasizes the importance of understanding the biology of different cell types to identify vulnerabilities that can be targeted with treatment. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So my lab currently is working on… so we sort of started, you know, focused on type one versus type two CALR mutations. Now we’ve broadened more to all driver mutations and MPNs and trying to understand what are the dependencies specific to different cell types. So we’re really interested in like metabolic dependencies of the mutant stem cell compartment and then as the cells differentiate, how do their needs change, like how does metabolism change, how does immune surveillance change, and how can we use that information then to eradicate those cells, which in theory would be curative, so that’s our goal is to really deeply understand the biology of these different cell types and use that information to be able to completely get rid of those cells from the body...
So my lab currently is working on… so we sort of started, you know, focused on type one versus type two CALR mutations. Now we’ve broadened more to all driver mutations and MPNs and trying to understand what are the dependencies specific to different cell types. So we’re really interested in like metabolic dependencies of the mutant stem cell compartment and then as the cells differentiate, how do their needs change, like how does metabolism change, how does immune surveillance change, and how can we use that information then to eradicate those cells, which in theory would be curative, so that’s our goal is to really deeply understand the biology of these different cell types and use that information to be able to completely get rid of those cells from the body.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultant for Paragon Therapeutics; Collaboration with Incyte.
